 This is a dose-escalation study. All patients will be treated with paromomycin and azithromycin. The initial group will be treated with either 110 ngkg IL-12 6 patients or placebo injections 2 patients twice a week for 4 weeks. If the initial dose is ineffective and the combination of drugs is tolerated, a second group of patients will be randomized to either 300 ngkg IL-12 6 patients or placebo injections 2 patients twice a week for 4 weeks. Patients will be evaluated for eradication of the parasite as measured by immunofluorescence and intestinal biopsy, decreases in stool frequency, decreases in 24 hour stool volume, stimulation of intestinal Th1 cytokine production, increases in body weight, improvements in Karnofsky score, and improvements in serum alkaline phosphatase levels and transaminases if elevated at baseline. 